Table 1

Demographics and screening characteristics for ≥1-year studies in patients with COPD by baseline blood eosinophil level and treatment group: INSPIRE (SCO40036)

Characteristic FP/SALTiotropium
<2%≥2%<2%≥2%
n263371287348
Age, mean (SD)64.1 (8.79)64.3 (8.06)64.8 (8.05)64.4 (8.46)
Male (%)79828186
Current smokers (%)42354136
Pack-years, median (range)38.0 (10–140)38.0 (–50–201)*38.0 (4–248)35.0 (3–151)
Post-BD FEV1% predicted, mean (SD)38.8 (8.14)39.3 (8.34)39.3 (9.20)39.5 (8.67)
FEV1% reversibility, mean (SD)2.4 (3.14)2.2 (4.29)2.6 (4.34)†2.7 (4.44)
Moderate/severe exacerbations in prior 12 months, n (%)
 069 (26)111 (30)89 (31)84 (24)
 175 (29)111 (30)92 (32)97 (28)
 251 (19)71 (19)55 (19)92 (26)
 >268 (26)78 (21)51 (18)75 (22)
  • *Negative value was recorded in dataset.

  • †n=285.

  • BD, bronchodilator; FP, fluticasone propionate; SAL, salmeterol.